Thyroid cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Natural History Study of Children and Adults With Medullary Thyroid Cancer

  NCT01660984· National Cancer Institute (NCI)· Source

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Source

• Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma

  NCT07911761· Mansoura University· Source

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

  NCT07886905· Washington University School of Medicine· Source

• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

  NCT01896479· Exelixis· Source

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

• A Study of Avutometinib and Defactinib in People With Thyroid Cancer

  NCT06007924· Memorial Sloan Kettering Cancer Center· Source

• Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

  NCT07529080· University of Michigan Rogel Cancer Center· Source

• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

  NCT07822880· Eli Lilly and Company· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• Incorporating natural language processing-derived features from pathology reports into machine learning models to predict differentiated thyroid cancer recurrence.

  Front Endocrinol (Lausanne), Oct 2026

• Network pharmacology and machine learning reveal kit as a target of roburic acid in anaplastic thyroid carcinoma: Preliminary in vitro validation.

  PLoS One, Oct 2026

• A genetic algorithm-optimized EWMA control chart integrating machine learning-based risk prediction for multistage thyroid cancer treatment monitoring.

  PLoS One, Oct 2026

• An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation.

  Front Endocrinol (Lausanne), Oct 2026

• Machine learning-based prediction of lymph node metastasis in papillary thyroid carcinoma: an interpretable multidimensional model.

  Front Endocrinol (Lausanne), Sept 2026

• Machine learning diagnostic model integrating ultrasound features and immune-inflammatory biomarkers for identifying papillary thyroid carcinoma in patients with Hashimoto's thyroiditis.

  Front Immunol, Sept 2026

• The value of machine learning models in predicting lung metastasis in papillary thyroid carcinoma.

  Front Endocrinol (Lausanne), Sept 2026

• Quantitative Super-Resolution Ultrasound Microvascular Features for Machine Learning-Based Classification of Thyroid Nodules.

  J Vis Exp, Sept 2026

• Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.

  Ann Med, Sept 2026

• Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach.

  Front Endocrinol (Lausanne), Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.